Detergents, specifically polidocanol and sodium tetradecyl sulphate, dominate the agent segment. Their popularity stems from their versatile therapeutic applications in both clinical and cosmetic treatments, as well as their effective endothelial penetration.
Foam sclerotherapy is the fastest-growing procedural type because it provides superior contact with the vein wall by displacing blood within the vessel. This increases treatment efficacy in larger varicosities and, when combined with ultrasound guidance, allows for higher precision in deeper venous structures.
While sclerotherapy is used for various pathologies, the varicose veins segment is the dominant application. Other significant applications include the treatment of hemorrhoids, malformed lymph vessels, hydroceles, and cosmetic spider veins.
North America holds the leading market share due to its advanced vascular care infrastructure, high procedural volumes, and strong demand for minimally invasive cosmetic treatments, supported by favorable insurance reimbursement for chronic venous insufficiency.
The Asia-Pacific region is anticipated to register the fastest CAGR. This growth is driven by increasing patient awareness of venous diseases, government investments in healthcare modernization, and the expansion of private vascular clinics in countries like China, India, and South Korea.
There is a significant industry shift toward non-surgical practices in outpatient settings. Healthcare systems favor sclerotherapy because it is cost-effective, requires minimal recovery time, and avoids the need for complex hospitalization or general anesthesia, making it attractive to both providers and payers.
Real-time ultrasound imaging is being integrated into delivery technologies to enhance procedural precision and safety. It allows for better access to deep veins, reduces the risk of complications, and increases overall clinician and patient confidence in the results.
In January 2024, Merz Aesthetics expanded the launch of Asclera (polidocanol injectable foam) into Asia and Latin America. Additionally, in 2023, BTG International (part of Boston Scientific) announced a new generation of microfoam sclerosants, and Medtronic collaborated with European clinics to integrate ultrasound-guided services.
Key obstacles include limited awareness of venous diseases in rural or underdeveloped regions, a shortage of trained vascular specialists in emerging markets, variable international reimbursement policies, and stringent regulatory pathways for the approval of new sclerosant formulations.
